Certificate

Brand

Illumina

Product Type

Instrument

Highlights

Illumina's smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs

Model: iSeq 100
Manufacturer: Illumina/USA
Illumina’s smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs
– Fast data generation: Suitable for small projects, on a dedicated device, low throughput with fast turnaround times
– Convenient operation: Control the sequencing process from start to finish and ensure independent sequencing instead of outsourcing.

Application
  • Target Sequencing (amplicon, gene panel)
  •  Small whole genome sequencing (bacteria, viruses)
  • Profiling target gene expression
  • Long Sequencing Amplicon
  • Analysis and miRNAs and small RNAs
Specifications

– Average running time from 9–17.5 hours
– Maximum capacity of 1.2 Gb;
– Maximum number of reading passages per run: 4 million;
– Maximum reading length 2 × 150 bp
– Dimensions 42.5 cm × 30.5 cm × 33 cm (16.8 in × 12 in × 13 in)
Weight 15.9 kg (35 lb)

Read length Total time Output
1 × 36 bp 9 hours 144 Mb
1 × 50 bp 9 hours 200 Mb
1 × 75 bp 10 hours 300 Mb
2 × 75 bp 13 hours 600 Mb
2 × 150 bp 17.5 hours 1.2 Gb

Details: https://sapac.illumina.com/systems/sequencing-platforms/iseq.html

Related Products

Solution: NgeneBio – SOLIDaccuTest™

SOLIDaccuTest™ is an excellent tool to explorer variants associated with solid tumors using a comprehensive method of next-generation sequencing (NGS). It reflects the latest research trends and is optimized for the medical purpose by selecting essential genes of solid tumors including lung, colon, breast, skin brain, gastric, ovarian cancers, etc.

 

BRCAaccuTest™ & BRCAaccuTest™PLUS

BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test

BRCAaccuTest™ & BRCAaccuTest™PLUS

BRCAaccuTest™ & BRCAaccuTest™PLUS is a regent for producing libraries for
analyzing the BRCA ½ genes using the NGS (next-generation sequencing) method,
which analyzes genomic DNA derived from blood or FFPE tissues.

Next Generation Sequencing System – NovaSeq 6000

Model: NovaSeq 6000
Manufacturer: Illumina/USA
– Scalable platform
Match data output, time to results, and price per sample to study needs
– Flexible performance
Configure sequencing method, flow cell type, and read length to support a broad range of applications
– Streamlined operation
Increase lab efficiency with a simplified workflow and reduced hands-on time

Next-Generation Sequencing System – NextSeq 2000

 The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.

PANARealTyperTM HPV Screening Kit

The PANA RealTyper™ HPV Screening Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC

PANARealTyperTM HPV Kit

PANA RealTyperTM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.

DxFLEX

DxFLEX is a new clinical flow cytometry platform derived from the successful CytoFLEX. The advanced sensitivity and intuitive software DxFLEX makes flow cytometry routine for both novice and expert flow cytometry technicians and promotes standardization. Functionality in the autoloader facilitates accurate results and sample tracking.

 

TruSight® Tumor 26

TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants

TruSight Cancer Sequencing Panel

Developed with cancer genomics experts in collaboration, oligos ready-to-use, pre-engineered oligos allow researchers to sequence a wide range of genes and single nucleotide polymorphisms (SNPs) in advance. this is related to cancer predisposition